Syria coronavirus spike sees hospitals reach capacity

Credit: Pixabay/CC0 Public Domain

Hospitals in the Syrian capital Damascus and the coastal province of Latakia have reached capacity due to rising coronavirus admissions, a health official said Sunday.

“We have started transferring COVID-19 patients from the of Damascus to the (central) province of Homs, and from Latakia to the province of Tartus,” Tawfiq Hasaba, a ministry official, was quoted as saying by Syrian state TV.

The move came after “hospitals in these areas reached capacity because of a large spike in coronavirus cases,” he added.

Syria on Saturday logged 442 new coronavirus infections in government-held areas—a new daily record for a conflict-hit country that has documented more than 32,580 cases, including 2,198 deaths in regime controlled territory, since the start of its outbreak last year.

“It is the first time the number of cases reaches 400” in one day, Hasaba said, adding that the number of new infections was highest in Damascus, Aleppo and Latakia.

Coronavirus cases have been on the rise across Syria since mid-August, including in the northwest and northeast, large parts of which fall beyond .

According to the World Health Organization, only two percent of Syria’s population has been at least partially vaccinated.

Syria’s conflict has since 2011 killed nearly half a million people and ravaged a healthcare sector struggling to cope with a mass outflux of professionals.

Around 70 percent of the country’s pre-war have left since the start of the war.

© 2021 AFP

Citation: Syria coronavirus spike sees hospitals reach capacity (2021, September 26) retrieved 2 October 2021 from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Antisense Oligonucleotide Shows Potential in Dravet Syndrome thumbnail

Antisense Oligonucleotide Shows Potential in Dravet Syndrome

Meeting Coverage > AES — Investigational STK-001 appears well tolerated in early studies by Judy George, Deputy Managing Editor, MedPage Today December 9, 2022 Last Updated December 12, 2022 Multiple doses of STK-001, an investigational antisense oligonucleotide to treat Dravet syndrome, were well tolerated and showed trends toward fewer seizures, interim analyses of phase I/IIa
Read More
Hayat Hanım thumbnail

Hayat Hanım

“İstediği her şeyi büyük bir tutkuyla istiyordu: Bir lambayı, oynak bir şarkıyla dans etmeyi, beni, bir şeftaliyi, sevişmeyi, lezzetli bir yemeği… Ama tutkuyla istediği her şeyden o tutku kadar güçlü bir aldırmazlıkla vazgeçebileceğini de hissediyordum. Her şeyi isteme hakkına, her şeyden vazgeçme gücüne sahipmiş gibi davranıyordu. Sanırım isteklerindeki doğal sınırsızlık, vazgeçebileceğine olan büyük inancından kaynaklanıyordu.…
Read More
Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma thumbnail

Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant increase in the risk of second primary malignancies associated with lenalidomide across all cancers (risk ratio [RR] 1.16, 95% CI 0.96-1.39), there was an increased risk associated with the
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?